Danaher gains FDA nod for AI AFib detection

Danaher has obtained U.S. Food and Drug Administration clearance for an artificial intelligence-enabled platform that helps detect atrial fibrillation, a common heart rhythm disorder that often goes undetected and increases the risk of stroke. The newly cleared capability is part of the Masimo smartSET platform and is designed to identify patients earlier who may benefit from further medical evaluation and care. Company leadership described this clearance as a significant extension of Masimo’s technology from pure monitoring into the detection of important clinical conditions.

The AFib detection clearance was highlighted as the Masimo team’s sixth FDA clearance this year, underscoring a rapid pace of regulatory-approved innovation. Executives emphasized that the technology integrates AI to support clinicians in recognizing atrial fibrillation, which can be difficult to diagnose in routine settings. By embedding AI-driven analytics into Masimo’s monitoring ecosystem, the platform is intended to enhance clinical workflows while maintaining continuity with existing devices and systems.

Masimo’s smartSET AFib platform sits within Danaher’s broader diagnostics and patient monitoring offerings. In its first full quarter as part of Danaher, Masimo delivered high single-digit revenue growth, illustrating early commercial momentum under the new ownership structure. Integration efforts were described as progressing, with identified opportunities for cost savings and commercial synergies across Danaher’s businesses.

The new FDA clearance is positioned as part of this integration, leveraging Danaher’s scale and Masimo’s sensor and monitoring technologies to develop AI-based diagnostic support tools. Management framed the smartSET AFib capability as an example of how Masimo’s innovations can be broadened beyond traditional monitoring, creating additional value in clinical decision support. These developments align with Danaher’s strategy of investing in advanced diagnostics to support earlier and more precise detection of disease.

Alongside the regulatory milestone, Danaher reported solid financial performance for the third quarter of 2026. Sales totaled $6.6 billion, and core revenue growth excluding respiratory revenue was 5.5%, representing a 100-basis-point acceleration from the second quarter. Respiratory revenue acted as a headwind, but core revenue in the Diagnostics segment excluding respiratory revenue grew 7%, with clinical diagnostics businesses increasing revenue by mid-single digits.

Leica Biosystems delivered notable performance within diagnostics, benefiting from strong momentum in digital pathology and advanced staining. Overall adjusted operating margin for the third quarter was 29%, and adjusted earnings per share increased 11.5% to $2.11. For the fourth quarter, Danaher expects an adjusted operating profit margin of approximately 29.5% and anticipates respiratory revenue to be a 150-basis-point headwind.

Reflecting year-to-date performance and the outlook, Danaher raised its full-year 2026 adjusted diluted net earnings per share guidance to a range of $8.57 to $8.62, compared with a prior range of $8.45 to $8.60. Management linked the guidance increase to better-than-expected growth, earnings, and cash flow. The combination of the AI AFib detection clearance, Masimo’s growth contribution, and resilient diagnostics demand was presented as supporting Danaher’s near-term financial trajectory.

Beyond AFib detection, Danaher is also advancing broader applications of artificial intelligence across its operations. The company has announced plans for its first AI-powered autonomous lab, integrating AI, robotics, and technologies from across the group into a continuous learning workflow. This initiative aims to connect AI directly to physical experiments, moving beyond simply asking AI what the next experiment should be toward executing and refining those experiments in an automated environment.

Taken together, the FDA clearance for Masimo’s smartSET atrial fibrillation detection platform and the development of an AI-powered autonomous lab highlight Danaher’s focus on embedding AI in both clinical and research workflows. These steps, combined with steady core growth and increased earnings guidance, frame AI-driven innovation as an important contributor to the company’s current and future performance.